Hologic, Inc. (NASDAQ:HOLX - Free Report) - Zacks Research lowered their FY2025 earnings per share estimates for Hologic in a research note issued on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $4.25 per share for the year, down from their previous estimate of $4.26. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.14 EPS and FY2026 earnings at $4.59 EPS.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.
Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada reduced their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Stephens reissued an "overweight" rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic has an average rating of "Hold" and an average price target of $84.62.
Read Our Latest Stock Analysis on HOLX
Hologic Stock Performance
Hologic stock traded down $1.09 during mid-day trading on Friday, reaching $60.80. 2,378,048 shares of the company were exchanged, compared to its average volume of 1,755,589. Hologic has a twelve month low of $60.34 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm's 50-day simple moving average is $65.70 and its two-hundred day simple moving average is $73.66. The firm has a market cap of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of HOLX. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter valued at about $26,000. Groupama Asset Managment boosted its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC grew its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the period. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.
About Hologic
(
Get Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Stories
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
